¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"secondary attack rate"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • secondary immune response
    ÀÌÂ÷¸é¿ª¹ÝÀÀ
  • secondary infection
    ÀÌÂ÷°¨¿°, ¼Ó¹ß°¨¿°
  • secondary keratitis
    ¼Ó¹ß°¢¸·¿°
  • secondary lysosome
    ÀÌÂ÷¿ëÇØ¼Òü
  • secondary nodule
    Á¾ÀÚÁß½É, ¹èÁß½É
  • secondary pneumonia
    ¼Ó¹ßÆó·Å
  • secondary process thinking
    ÀÌÂ÷°úÁ¤»ç°í
  • secondary sequestrum
    ÀÌÂ÷ºÎ°ñ, ºÎºÐºÐ¸®Á×Àº»À
  • secondary sex characteristic
    ÀÌÂ÷¼ºÂ¡
  • secondary sexual character
    ÀÌÂ÷¼ºÂ¡
  • secondary shock
    ÀÌÂ÷¼îÅ©, ¼Ó¹ß¼îÅ©
  • secondary sterility
    ¼Ó¹ßºÒÀÓ
  • secondary suture
    ÀÌÂ÷ºÀÇÕ
  • secondary tuberculosis
    ¼Ó¹ß°áÇÙ
  • secondary wound closure
    ÀÌÂ÷»óóºÀÇÕ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • fatality rate
    Ä¡¸í·ü
  • fertility rate
    »ý½Ä·ü, ¼öÅÂÀ²
  • fetal death rate
    žƻç¸Á·ü
  • fetal heart rate
    žƽɹڼö
  • five-year survival rate
    ¿À³â»ýÁ¸·ü
  • glomerular filtration rate
    Å丮¿©°úÀ², »ç±¸Ã¼¿©°úÀ²
  • heart rate
    ½ÉÀå¹Úµ¿¼ö
  • infant mortality rate
    ¿µ¾Æ»ç¸Á·ü
  • morbidity rate
    ÀÌȯ·ü
  • mortality rate
    »ç¸Á·ü
  • mutation rate
    µ¹¿¬º¯ÀÌÀ²
  • onset rate
    ¹ß»ý·ü
  • operative mortality rate
    ¼ö¼ú»ç¸Á·ü
  • peak expiratory flow rate
    ÃÖ°í³¯¼û¼Óµµ, ÃÖ°íÈ£±âÀ¯¼Ó
  • perfusion rate
    °ü·ù¼Óµµ, °ü·ùÀ²
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • secondary evoked response
    ÀÌÂ÷À¯¹ß¹ÝÀÀ
  • secondary immune response
    ÀÌÂ÷¸é¿ª¹ÝÀÀ
  • secondary
    ÀÌÂ÷-, Á¦ÀÌ-, ¼Ó¹ß-
  • secondary sequestrum
    ºÎºÐºÐ¸®Á×Àº»À, Á¦À̱âºÎ°ñ
  • secondary shock
    ÀÌÂ÷¼îÅ©
  • secondary sterility
    ÀÌÂ÷ºÒÀÓ(Áõ)
  • secondary suture
    ÀÌÂ÷ºÀÇÕ
  • secondary process thinking
    ÀÌÂ÷°úÁ¤»ç°í
  • abortion rate
    À¯»êÀ²
  • absorbed dose rate
    Èí¼ö¼±·®·ü
  • actual death rate
    ½ÇÁ¦»ç¸Á·ü
  • adjusted death rate
    (¢¡standardized death rate) Ç¥ÁØÈ­»ç¸Á·ü
  • age-specific rate
    ¿¬·Éº°Æ¯¼öÀ²
  • age-specific death rate
    ¿¬·Éº°Æ¯¼ö»ç¸Á·ü
  • age-specific fertility rate
    ¿¬·Éº°Ãâ»êÀ²
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • glomerular filtration rate
    »ç±¸Ã¼ ¿©°úÀ²
  • glomerular filtration rate
    »ç±¸Ã¼¿©°úÀ²
  • glomerular filtration rate =GFR
    »ç±¸Ã¼¿©°úÀ²(¡­ÕëΦëÏ).
  • glomerular filtration rate =GFR
    »ç±¸Ã¼¿©°úÀ².
  • gross reproduction rate
    ÃÑÀç»ý»êÀ².
  • growth rate
    ¼ºÀå·ü(ËÛËöËô).
  • growth rate constant
    Áõ½Ä·ü»ó¼ö
  • half elimination rate
    1/2Á¦°ÅÀ²(ð¶ËÛëÒ), ¹Ý°¨·ü(ÚâÊõ×Ë)
  • half elimination rate
    1/2Á¦°ÅÀ², ¹Ý°¨·ü.
  • heart rate
    ½É¹Ú¼ö, ½É(Àå)¹Úµ¿¼ö(ãýíôÚÑÔÑâ¦).
  • heart rate meter
    ½É¹Ú°è(ãýÚÑͪ), ½É(Àå)¹Úµ¿°è(ãýíôÚÑÔÑͪ)
  • heat transfer rate
    ¿­Àü´Þ·ü(¡­ëÒ).
  • heat transfer rate
    ¿­Àü´Þ·ü(ÊÙËô).
  • hebdomadal death rate
    »ýÈÄÀÏÁÖ°£»ç¸Á·ü(ÊÙË×ËÎËô).
  • high dose rate
    °í¼±·®À²
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • uncinate attack ; uncinate fit
    ±¸È¸(Àü)¹ßÀÛ(ÏÉüÞï®Û¡íÂ)
  • absorbed dose rate
    Èí¼ö¼±·®À²
  • actual death rate
    ½ÇÁ¦»ç¸Á·ü(ËàÌ¡Ë×ËÎËô).
  • adjusted death rate
    Á¶Á¤»ç¸Á·ü.
  • age specific death rate
    ¿¬·Éº° »ç¸Á·ü
  • air kerma-rate constant
    °ø±âÄ¿¸¶À²»ó¼ö
  • alveolar ventilation rate
    ÆóÆ÷ȯ±âºñ(¡­üµÑ¨Ýï)
  • arterial perfusion rate
    µ¿¸Æ°ü·ùÀ²
  • bacterial growth rate
    ¼¼±ÕÁõ½ÄÀ²
  • basal metabolic rate
    ±âÃÊ´ë»çÀ²(Ðìõ¨ÓÛÞóëÒ)
  • basal metabolic rate
    ±âÃÊ´ë»çÀ²(Ðñõ¨ÓÛÞóëÒ)
  • basal metabolic rate =BMR
    ±âÃÊ´ë»çÀ²(¡­ÓÛÞóëÒ)
  • bed turn over rate
    º´»óȸÀüÀ²
  • birth rate
    Ãâ»ý·ü(õóßæëÒ).
  • birth rate
    Ãâ»ý·ü(̧Ë×Ëô).
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • Haploid secondary gametocyte
    Ȭ¹è¼öüÀÌÂ÷»ý½Ä¼¼Æ÷
    [¿¾ ¿ë¾î] ¹Ý¼öüÁ¦ÀÌ»ý½Ä¼¼Æ÷
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • secondary ion mass spectrometry
    ÀÌÂ÷ ÀÌ¿ÂÁú·®ºÐ±¤¹ý(ì£ó­òõÕáÝÂÎÃÛö)
  • secondary isotope effect
    ÀÌÂ÷ µ¿À§¿ø¼ÒÈ¿°ú(ì£ó­ÔÒêÈêªáÈüùÍý)
  • secondary lysosome
    ÀÌÂ÷(ì£ó­) ¶óÀ̼ҼØ
  • secondary malnutrition
    ÀÌÂ÷ ¿µ¾ç½ÇÁ¶(ì£ó­ç½å×ã÷ðà)
  • secondary messenger
    ÀÌÂ÷ Àü·É (ì£ó­îîÖµ)
  • secondary metabolite
    ÀÌÂ÷ ´ë»ç¹°(ì£ó­ÓÛÞóÚª)
  • secondary plant constituent
    ÀÌÂ÷ ½Ä¹°¼ººÐ(ì£ó­ãÕÚªà÷ÝÂ)
  • secondary plot
    ÀÌÂ÷(ì£ó­) Ç÷Ô
  • secondary protein derivative
    ÀÌÂ÷ ´Ü¹éÁúÀ¯µµÃ¼(ì£ó­Ó±ÛÜòõë¯Óôô÷)
  • secondary solvent
    ÀÌÂ÷ ¿ë¸Å(ì£ó­éÁØÚ)
  • secondary standard
    ÀÌÂ÷ Ç¥ÁØ(ì£ó­øöñÞ)
  • secondary structure
    ÀÌÂ÷ ±¸Á¶(ì£ó­Ï°ðã)
  • super-secondary structure
    ÃÊÀÌÂ÷ ±¸Á¶(õ±ì£ó­Ï°ðã)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
TIA Transient Ischemic Attack; Temporary Interference with the blood supply to the brain
AAA abdominal aortic aneurysm/aneurysmectomy; acne-associated arthritis; acquired aplastic anemia; acute...
ALLHAT Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial
ASA acetylsalicylic acid; active systemic anaphylaxis; Adams-Stokes attack; American Society of Anesthes...
BHAT Beta Blocker Heart Attack Trial
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
SLC Secondary Lymphoid-tissue Chemokine
SP Secondary Polycythaemia
SIMS Secondary ion mass spectroscopy
SP Secondary progressive
ToF-SIMS Time of Flight Secondary Ion Mass Spectrometry
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • secondary pain
    ¼Ó¹ß¼º ÅëÁõ, Á¦ÀÌ µ¿Åë
    µ¿ÀǾî=referred
  • secondary palate
    ÀÌÂ÷ ±¸°³
  • secondary pathway
    ÀÌÂ÷ °æ·Î
  • secondary pneumonia
    ¼Ó¹ß¼º Æó·Å
  • secondary sex characteristic
    ÀÌÂ÷ ¼ºÂ¡
  • secondary source
    ÀÌÂ÷ ¿äÀÎ
  • secondary sterility
    ¼Ó¹ß ºÒÀÓ
  • secondary structure
    ÀÌÂ÷ ±¸Á¶
  • secondary syphilis
    ÀÌÂ÷ ¸Åµ¶, 2±â ¸Åµ¶
    s
  • secondary thrombocytopenia
    ÀÌÂ÷¼º Ç÷¼ÒÆÇ °¨¼ÒÁõ
  • secondary tuberculosis
    ÀÌÂ÷¼º °áÇÙ
  • secondary vaccinia
    ÀÌÂ÷ ¹é½Å
  • absorptace rate
    Èí¼öÀ²
    ÀÎü¿¡ Á¶»çµÇ´Â ¹æ»ç¼±¿¡ ´ëÇØ ÀÎü¿¡ Èí¼öµÇ´Â ¹æ»ç¼± ¿¡³ÊÁöÀÇ ºñÀ².
  • absorption rate
    Èí¼öÀ²
    ÀÏÁ¤ ½Ã°£¿¡ »¡¾ÆµéÀÌ´Â ¼Óµµ¸¦ ³ªÅ¸³»´Â À².
  • adjusted death rate
    Á¶Á¤ »ç¸Á·ü
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
rate, heart Number of heart beats per minute. The normal resting adult heart beats regularly at an average rate of 60 times per minute. (young children's hearts beat faster). The speed of the heartbeat (heart rate) is governed by the speed of electrical signals from the pacemaker of the heart, the sa node, located in the right atrium (upper chamber of the heart). The electrical signals from the sa node travel across the atria and cause these two upper heart chambers to contract, delivering blood into the lower heart chambers, the ventricles. The electrical signals then pass through the av node to reach the ventricles. Electrical signals reaching the ventricles cause these chambers to contract, pumping blood to the rest of the body, generating the pulse. During rest, the speed of electrical signals originating from the sa node is slow, so the heart beats slowly. During exercise or excitement, the speed of signals from the sa node increases, and the heartbeat quickens.
(12 Dec 1998)
rate, infant mortality The number of children dying under a year of age divided by the number of live births that year. The infant mortality rate in the united states, which was 12.5 per 1,000 live births in 1980, fell to 9.2 per 1,000 live births in 1990.
(12 Dec 1998)
rate-limiting step <biochemistry> The slowest step in a metabolic pathway, or the step in an enzymatic reaction that requires the greatest amount of energy to initiate.
(17 Dec 1997)
rate, maternal mortality The number of maternal deaths related to childbearing divided by the number of live births (or by the number of live births + foetal deaths) in that year. The maternal mortality rate in the united states in 1993 (and 1994) was 0.1 per 1,000 live births, or 1 mother dying per 10,000 live births.
(12 Dec 1998)
rate meter A device that continuously displays the magnitude of events averaged over varying time intervals.
(05 Mar 2000)
rate, neonatal mortality The number of children dying under 28 days of age divided by the number of live births that year. The neonatal mortality rate in the united states, which was 8.4 per 1,000 live births in 1980, declined to 5.8 per 1,000 live births in 1990.
(12 Dec 1998)
rate, pulse The pulse rate is most often taken at the wrist. It measures the number of pulsations in the radial artery each minute.
(12 Dec 1998)
rate, respiratory The number of breaths per minute (or, more formally, the number of movements indicative of inspiration and expiration per unit time). In practice, the respiratory rate is usually determined by counting the number of times the chest rises (or falls) per minute. By whatever means, the aim is to determine if the respirations are normal, abnormally fast (tachypnea), abnormally slow (technically termed bradypnea), or nonexistent (apnea).
(12 Dec 1998)
rate schedule A price list showing how the electric bill of a particular type of customer will be calculated by an electric utility company.
(05 Dec 1998)
rate, sed A sedimentation rate, or sed rate , is a blood test that detects and is used to monitor inflammation activity. It is measured by recording the rate at which red blood cells (rbcs) sediment in a tube over time. It increases (the rbcs sediment faster) with more inflammation.
(12 Dec 1998)
rate, sedimentation A sedimentation rate, or sed rate , is a blood test that detects and is used to monitor inflammation activity. It is measured by recording the rate at which red blood cells (rbcs) sediment in a tube over time. It increases (the rbcs sediment faster) with more inflammation.
(12 Dec 1998)
rate setting and review A method of examining and setting levels of payments.
(12 Dec 1998)
general fertility rate A refined measure of fertility in a population; the numerator is the number of live births in a year, the denominator is the number of females of child-bearing age, usually defined as ages 15-44 (but increasingly recognised as extending to age 49).
(05 Mar 2000)
recurrence rate In genetic counseling, the risk that a future offspring will be affected given some specific set of relatives of whom at least one is already affected.
(05 Mar 2000)
case fatality rate The proportion of individuals contracting a disease that die of that disease.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • coupon rate
    ä±ÇÀÇ Ç¥¸é ÀÌÀÚÀ²
  • cross rate
    Å©·Î½º ·¹ÀÌÆ®;¿µ.¹Ì ȯ½Ã¼¼
  • death rate
    »ç¸Á·ü(mortality)
  • differential rate
    (öµµ µîÀÇ)ƯÁ¤ ¿îÀÓ·ü
  • discount rate
    ¾îÀ½ ÇÒÀÎÀ²;ÀçÇÒÀÎÀ²
  • economic growth rate
    °æÁ¦ ¼ºÀå·ü 9
  • effective exchange rate
    (±ÝÀ¶)½ÇÈ¿ ȯ½Ã¼¼(ȯÀ²)(±¹Á¦ÅëÈ­±â±ÝÀÌ ´çÇØ±¹°ú ´Ù¸¥ ÁÖ¿ä 20°³±¹ ÅëÈ­ÀÇ È¯½Ã¼¼¸¦ º¹ÇÕ½ÃÄÑ »êÃâÇÏ´Â Áö¼ö)
  • exchange rate
    ȯÀ²
  • fatality rate
    »ç¸Á·ü
  • fixed exchange rate(system)
    °íÁ¤È¯½Ã¼¼(Á¦)
  • flat rate
    °íÁ¤(Á¤¾×)¿ä±Ý
  • floating exchange rate system
    º¯µ¿ ȯÀ²Á¦
  • floating rate
    ÀÚÀ¯ º¯µ¿ ½Ã¼¼;¼±Çϼ¼
  • forward rate
    (¿Ü±¹È¯ÀÇ) ¼±¹° ½Ã¼¼
  • freight rate
    ¿îÀÓ·ü Àå
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á